Innovation in Healthcare:Opportunity + Capability

We are passionate about workingat the very forefront

of biomedical scienceand technology, making

changes to patients’ lives.

We strive to make things better,and, in our view, that’s theonly way to do business intoday’s highly-competitive

global environment.

● Evergreen private VC fund with $200M as initial commitment

● Focus on drug discovery and development

● Led by biotech entrepreneurs with outstanding track record

● Backed by the national industry champions (Generium and Pharmstandard)

● World-class R&D infrastructure and expertise

● Unmatched market access capabilities in Russia/CIS

● Worldwide outreach through ongoing partnerships with 1st and 2nd tier pharma, VC firms and centers of innovation

● Easy access to KOLs in major therapeutic areas

1

Investment Focus

2

We are looking for innovative projects

targeting unmet medical needs or

providing dramatic advantages over the competition

globally

In-licensing / Partnering / Co-development

● Inbio Ventures would normally consider in-licensing opportunity for the territory of Russia/CIS ● We can consider partnering with promising early-stage biopharmaceutical start-ups ● Through our strategic alignment with IBC Generium R&D center we could offer a broad range of

services adding value to the project

Therapeutic Areas of the highest priority

● Oncology

● Inflammation

● Autoimmune diseases

● Orphan genetic diseases

● Critical care

● Cell-based therapy and regenerative medicine

Late Preclinical to Phase III

Portfolio

3

Equi

ty In

vest

men

t

Argos Therapeutics (USA, NASDAQ:ARGS)

Fully personalized immunotherapies for the treatment of cancer and infectious diseases

Aquinox Pharmaceuticals(USA, Canada, NASDAQ:AQXP)

Novel targeted small molecule therapeutics for the treatment of cancer and inflammatory diseases

Protagonist Therapeutics(USA-Australia)

Disulfide-rich peptides as orally applicable alternatives to biologics

Proteon Therapeutics (USA, NASDAQ:PRTO)

First-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases

Allena Pharmaceuticals(USA)

Non-systemic protein therapeutics to treat metabolic and orphan diseases

enGene(Canada)

Highly flexible nucleotide delivery technology targeting mucosal tissues

Jounce Therapeutics(USA)

Novel biological insights to drive the development of game-changing immunotherapy treatments

Dev

elop

men

t Co

-Dev

elop

men

t Affitech(Norway, Denmark)

Fully human antibodies for cancer and other diseases with high unmet medical needs

Co.don(Germany)

Tissue engineering/regenerative medicine

Alethia Biotherapeutics(Canada)

Therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets

ProMetic Life Sciences(Canada, TSX:PLI)

Human plasma-derived therapeutic protein fractionation

Investment Strategy

4

Inbio Ventures

Global development

Research & Development

ManufacturingMarketing

Marketing Sales

Local drug development

VC investment License opportunityfor Russian and CIS territories

Pharmaceuticals

5

● No.1 Pharmaceutical company in Russia ● Listed at London Stock Exchange and MICEX-RTS (PHST) ● Revenue about $1.1B (2014), EBITDA 36% ● About 7 000 employees ● Over 250 products (Rx and OTC) ● Over 70 new launches in 2005-2014 ● Long-term partnerships with J&J, Roche, Abbott ● 8 modernized pharmaceutical plants, 6 GMP production lines,

full production cycle

● Pharmastandard’s spin-off in the field of over-the-counter pharmaceutical market

● Leadership position across the key segments of Russian pharma market, including Antivirals (anti-flu), Antifungals, NSAIDs, Analgesics, Anxiolytics, Probiotics, Multivitamins, etc.

● 27 OTC brands in various therapeutic categories ● Net revenue $430M (2014), EBITDA 43% ● Distribution network all over the country

6

7

Scientific Research Company & Manufacturing CompanyGenerium Group

● Full cycle biopharmaceuticals development and production, including fully-human mAbs

● Variety of expression systems

● Proprietary animal models to study cancer, inflammation, and other diseases

● 5000L combined bioreactor capacity

● About 65 scientific and 175 manufacturing employees

● Over 35 products in the pipeline (innovative and biosimilars)

● Seven products on the market, 5 product licensed out for other territories

● Individual project research with leading biotechnology companies from Denmark, Switzerland, Germany, Israel, the United States, France, and Cuba.

Pharmaceuticals

Facilities

8

Pharmaceuticals

Res

earc

h

Antibody Discovery and Therapeutic Protein Expression

● Phage display ● Matrix assisted, living cells ● Proprietary IgG, IgM/D libraries ● HTP automated screening bioassays

● Enzymes ● Cytokines ● Growth factors ● Glycoengineering ● PK improvement technologies

PreC

T &

CT ● PoC pharmacology studies

● Increasing spectrum of available animal models ● IND enabling toxicology, PK and PD studies (rodents, rabbits, NHPs) ● GCP-compliant Clinical trials in Russia, CIS, and worldwide

Man

ufac

turi

ng

● Cell Line Development, Cell Line Engineering ● Upstream and Downstream Process Development ● Broad range of upstream processing devices ● Pilot Manufacturing (5-200L) ● GMP-compliant Commercial Production of Biologically Active Substances (3x1000L,

disposables) ● Production of Finished Dosage Forms ● Fill-and-Finish of sterile lyophilized or liquid dosage forms ● Analytics and Quality Control

Cellthera Medical Drugs for Regenerative Medicine

9

Cellthera is a spin-off company that has been organized with the aim to transfer advanced biomedical technologies to the Russian Federation.

The first asset to be transferred is German company Co.don that has developed a unique technology to repair damage of the articular (hyaline) cartilage surfaces by transplantation of cartilage cells (chondrocytes) that have been taken from the patient.

Cell therapy approaches

● Cell therapy for regenerative medicine ● Autologous anti-cancer vaccine

Another asset is one of the Inbio Ventures’ portfolio companies Argos Therapeutics, developing dendritic-cells based vaccines using its Arcelis™ platform. Arcelis™ is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient’s disease.

GMP-compliant facility has been recently

constructed within the IBC Generium building

Generium Projects (selected)

10

Name Description Area of Treatment Type Discovery Preclinical Studies Clinical Studies Commercial Production

Diaskintest® Subcutaneous tuberculosis infection test Mass screening to reliably detect tuberculosis infection Innovative

Coagil®-VII Human blood coagulation factor VIII Hemophilia,Type A Biosimilar

Infibeta® Interferon beta-1b Multiple sclerosis Biosimilar

Rastan® Human Growth Hormone Growth hormone deficiency, Shereshevsky-Turner syndrome, chronic renal failure in children Biosimilar

Filgrastim Human G-CSF Neutropenia (oncology, transplantation, HIV infection) Biosimilar

Octofactor® Human blood coagulation factor VIII Hemophilia,Type A Biosimilar

Innonafactor® Human blood coagulation factor IX Hemophilia,Type B Biosimilar

Reveliza® Tissue plasminogen activator Cardiovascular diseases (myocardial infarction, pulmonary embolism) Biosimilar

Apagin® Anti-VEGF antibody Oncology (metastatic colorectal cancer, breast cancer, lung cancer) Innovative

GNR-016 Anti-clusterin antibody Oncology Innovative

GNR-027 Anti-HER2 Oncology (HER2+ solid tumors) Innovative

GNR-008 Imiglucerase Rare genetic diseases (Gaucher’s disease) Biosimilar

GNR-043 Anti-CXCR antibody Oncology Innovative

GNR-006 Anti-CD20 antibody Oncology (Non-Hodgkin’s lymphomas) Biosimilar

GNR-021 Factor VIII modified Hemophilia, Type A Innovative

GNR-047 The bispecific antibody B-cell lymphomas Innovative

GNR-007 Anti-RSV antibody Infectious diseases Biosimilar

11

Pharmaceuticals

Name Description Area of Treatment Type Discovery Preclinical Studies Clinical Studies Commercial Production

Diaskintest® Subcutaneous tuberculosis infection test Mass screening to reliably detect tuberculosis infection Innovative

Coagil®-VII Human blood coagulation factor VIII Hemophilia,Type A Biosimilar

Infibeta® Interferon beta-1b Multiple sclerosis Biosimilar

Rastan® Human Growth Hormone Growth hormone deficiency, Shereshevsky-Turner syndrome, chronic renal failure in children Biosimilar

Filgrastim Human G-CSF Neutropenia (oncology, transplantation, HIV infection) Biosimilar

Octofactor® Human blood coagulation factor VIII Hemophilia,Type A Biosimilar

Innonafactor® Human blood coagulation factor IX Hemophilia,Type B Biosimilar

Reveliza® Tissue plasminogen activator Cardiovascular diseases (myocardial infarction, pulmonary embolism) Biosimilar

Apagin® Anti-VEGF antibody Oncology (metastatic colorectal cancer, breast cancer, lung cancer) Innovative

GNR-016 Anti-clusterin antibody Oncology Innovative

GNR-027 Anti-HER2 Oncology (HER2+ solid tumors) Innovative

GNR-008 Imiglucerase Rare genetic diseases (Gaucher’s disease) Biosimilar

GNR-043 Anti-CXCR antibody Oncology Innovative

GNR-006 Anti-CD20 antibody Oncology (Non-Hodgkin’s lymphomas) Biosimilar

GNR-021 Factor VIII modified Hemophilia, Type A Innovative

GNR-047 The bispecific antibody B-cell lymphomas Innovative

GNR-007 Anti-RSV antibody Infectious diseases Biosimilar

Inbio ManagementAlexander Shuster, PhD. General Partner

● A serial drug discovery entrepreneur with a track record of companies successfully commercialized through M&A and licensing deals

● President of IBC Generium, Member of the Board of OJSC Pharmstandard and Chairman of the Board of Affitech (Norway, Denmark)

Andrei Petrov, PhD. Founder and Managing partner, CEO

● Extensive experience in molecular biology, cell biology and immunology

● Member of the Board of Affitech AS (Norway, Denmark), co.don AG (Germany), and Argos Therapeutics (USA)

● Till 2011 Dr. Petrov was Chief Scientific Officer of International Biotechnology Center Generium

Alexey Vinogradov, PhD. Managing partner, CBO

● A solid academic background in biochemistry with 10+ years’ experience in business development

● Member of the Board of Argos Therapeutics (USA) and Protagonist Therapeutics (USA, Australia)

● Established several dozens of early-stage start-ups through seed funding mechanisms

12

Inbio Ventures10 Testovskaya street,Moscow 123317Russian FederationPhone +7 495 988 47 95Fax +7 495 988 47 92info@inbiovent.comwww.inbiovent.com